TORONTO, ON / ACCESSWIRE / February 14, 2020 / The Company HDII (OTC PINK:HDII) Hypertension Diagnostics Inc. would like to inform the Shareholders at this time that: the Company is fully confident of taking Legal Action against Mr. Brimmer in regard to his unlawful claims.
Mr. Liangjian Peng, the current CEO of Hypertension Diagnostics Inc. states that “I will continue looking for the best merge target. I believe that HDII will make great strides in 2020, the year of rat . We will always operate ethically, and fairly. I appreciates all shareholders and will continue to provide updates as I have them.”
About Hypertension Diagnostics Inc.
Hypertension Diagnostics, Inc. is a public company currently trading on the OTC Markets (OTC: PINK: HDII). HDII was originally corporate in Minnesota .
*Safe Harbor Statement Information in this press release may contain ‘forward-looking statements.’ Statements describing objectives or goals or the Company’s future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Hypertension Diagnostics Inc.’s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Hypertension Diagnostic Inc. periodic reports filed with the regulatory authorities.
CONTACT:
Jeff Peng
jeff.torcn.com@gmail.com
SOURCE: Hypertension Diagnostics Inc.
View source version on accesswire.com:
https://www.accesswire.com/576481/HYPERTENSION-DIAGNOSTICS-Inc-Announce-to-All-Shareholders
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION…
First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing…
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - Delivra Health Brands Inc. (TSXV: DHB)…
New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens…
Pioneering the Path of Sound Therapy with Biofield TuningBURLINGTON, VERMONT / ACCESSWIRE / March 20,…
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or…